Form 4: PTC Therapeutics Exec. VP Mark Boulding Executes Stock Options and Sells Shares Under 10b5-1 Plan

Mark Boulding, Executive VP and CLO of PTC Therapeutics, exercised stock options and sold shares of common stock on March 12, 2025, under a pre-arranged 10b5-1 trading plan.

Summary

• On March 12, 2025, Mark Elliott Boulding, Executive VP and CLO of PTC Therapeutics, executed stock options to acquire 13,126 shares and 2,395 shares of common stock at an exercise price of $33.02.
• Concurrently, Boulding sold 13,126 shares at a weighted average price of $53.31 and 2,395 shares at a weighted average price of $53.23.
• These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 5, 2024.
• Following these transactions, Boulding directly owns 103,901 shares of PTC Therapeutics common stock.
• The stock options are currently exercisable and expire on January 21, 2029.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transactions were executed under a pre-arranged 10b5-1 trading plan and do not necessarily reflect a change in the executive's outlook on the company.

Positives

• The transactions were executed under a pre-arranged 10b5-1 trading plan, which can mitigate concerns about insider trading.

Industry Context

Executive stock transactions are a common occurrence in publicly traded companies, and are often viewed by investors as a signal of management's confidence (or lack thereof) in the company's future prospects. Transactions executed under 10b5-1 plans are generally viewed as less informative, as they are pre-arranged and may not reflect the executive's current views.

Comparison to Industry Standards

• Executive compensation practices, including stock options and equity grants, are common across the biotechnology industry.
• Companies like Amgen, Biogen, and Gilead Sciences also utilize stock options as part of their executive compensation packages.
• The use of 10b5-1 trading plans is a standard practice among executives at publicly traded companies to manage their personal finances and avoid accusations of insider trading.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in ownership, but the impact is likely to be minimal given the relatively small number of shares involved.

Key Dates